2,4-Dioxo-3-quinazolinylaryl sulfonylurea compounds having the formula: ##STR00001## wherein R is a member selected from the group consisting of H and C.sub.1-6 alkyl; R.sup.1 is a member selected from the group consisting of H, C.sub.1-6 alkyl, C.sub.1-6 haloalkyl, C.sub.3-5 cycloalkyl and C.sub.3-5 cycloalkyl-alkyl; R.sup.2 is a member selected from the group consisting of H, halogen, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl, C.sub.1-6 alkoxy, cyano and --C(O)R.sup.2a, wherein R.sup.2a is a member selected from the group consisting of C.sub.1-6 alkoxy and (C.sub.1-6 alkyl).sub.0-2 amino; L is a 1 to 3 carbon linking group selected from the group consisting of --CH.sub.2--, --CH(CH.sub.3)--, --CH.sub.2CH.sub.2--, --CH.sub.2CH(CH.sub.3)-- and --CH.sub.2CH.sub.2CH.sub.2--; L.sup.1 is a linking group selected from the group consisting of a bond and --CH.sub.2--; L.sup.2 is a linking group selected from the group consisting of a bond, --NH-- and --CH.sub.2--; and Ar.sup.1 is an aromatic ring selected from the group consisting of benzene, pyridine and pyrimidine; are provided. The compounds are useful for the inhibition of ADP-platelet aggregation, particularly in the treatment of thrombosis and thrombosis related conditions or disorders.